🔎 Trials Near Me

Utama › Neuroblastoma › Wilayah Columbia

Kajian klinikal Neuroblastoma di Wilayah Columbia

6 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di Wilayah Columbia.

Bandar di Wilayah Columbia

Teks kajian rasmi (Bahasa Inggeris)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  • Children's National Hospital, Washington D.C.
  • Childrens National Hospital, Washington D.C.
Mengambil pesertaFasa 1
Umur 1 hingga 23 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT07172958

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
18 Months – 40 Years · Semua jantina · Dikemas kini 12 Ogo 2025 · NCT05135975

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.